Ľ,
-
5.
L
Q
T,
Q
6.6

	_	pon o	
,	$\sim$ $\sim$ $\alpha$		L
19	-()	DTO (00 f	
( ) (		PTO/SB/0	)5 £U3
$\mathcal{O}^{T}$	Approved for use thro	ough 10/31/2002. OMB 0	651-0
	LLC Detent and Tradamark Office LLC	DEDARTMENT OF COL	MARKET

Please type a plus sign (+) inside this box

(Only for new nonprovisions, applications under 37 CFR 1.53 (h))

Under the Paperwork Reduction Act of 1995, no persons are re	quired to re	spond to a collection of	information unless it displays a valid OMB control number	
UTILITY		ney Docket No.	LEX-0268-USA	
PATENT APPLICATION TRANSMITTAL	First I	nventor	Walke, et al.	
	Title	Novel Human Se the Same	creted Proteins and Polynucleotides Encoding	
for new nonprovision&, applications under 37 CFR			=======================================	

		1.53 (D))	L- 1		
-		CATION ELEMENTS 00 concerning utility patent application	on	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
1. 2. 3.	Applicant claim See 37 CFR 1 Specification (preferred arrangen  - Descriptive title of Cross Reference - Statement Regar - Reference to section or a computer programmer of the Brief Bushington - Detailed Description - Claim(s) - Abstract of the difference of the computer programmer or a computer	al Form (e.g., PTO/SB/17)  as small entity status.  .27.  [Total Pages 34]  If the Invention to Related Applications ding Fed sponsored R & D uence listing, a table, ogram listing appendix e Invention for Invention for Invention sclosure  U.S.C.113) [Total  [Total Pages 2		7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a. Computer Readable Form (CRF)  b. Specification Sequence Listing on:  i. X diskette  ii. X paper5 pages  c. X Statements verifying identity of above copies  ACCOMPANYING APPLICATION PARTS  9. Assignment Papers (cover sheet & document(s))  10. 37 CFR 3.73(b) Statement (when there is an assignee)  11. English Translation Document (if applicable)  12. Information Disclosure Copies of IDS Citations  13. Preliminary Amendment	
6.	b. Copy from for continua  i. DEL signe name 1.63(	a prior application (37 CFR 1.63(d)) tion/divisional with Box 18 completed)  ETION OF INVENTOR(S) and statement attached deleung inventor(s) and in the prior application, see 37 CFd)(2) and 1.33(b).  Sheet. See 37 CFR 1.76		14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15. Certified Copy of Priority Document(s) (if foreign priority is claimed)  16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent  17. Other:	
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:  Continuation Divisional Continuation-in-part (CIP) of prior application No.:  Group Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  19. CORRESPONDENCE ADDRESS  Customer Number or Bar Code Label  Or Correspondence address below					
	nme Idress	(Insert Customs	242.	ttach bar code label here)  NRK OFFIGE	
Cit		State		Zip	
_	ountry	Telephor		Fax	
F	Name (Print/Type)	Lance K. Ishimoto		Registration No. (Attorney/Agent) 41,866	
ŀ	Signature	Lance K. Sylviniste by D.	W. HBC		

PTO/SB/17 (11-00)
Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark office: U.S. DEPARTMENT OF COMMERCE
3 a collection of information unless it displays a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to

## **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

				_
TOTAL	AMOU	INT OF	PAYMENT	(\$)

Complete if Known				
Application Number	To be assigned			
Filing Date	November 9, 2001			
First Named Inventor	Yu et al.			
Examiner Name	To be assigned			
Group Art Unit	To be assigned			
Attorney Docket No.	LEX-0268-USA			

METHOD OF PAYMENT				FEE	CALCULATION (continued)	
The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to.				EES Small Entity		
Deposit Account Number 50-0892	Fee Code	Fee	Fee Code	Fee (\$)	Fee Description Fee Paid	٦
Deposit Account Lexicon Genetics Incorporated	105	130	205	65	Surcharge - late fling fee or oath	
Name Charge Any Additional Fee Required	127	50	227	25	Surcharge - late provisional filing fee or cover sheet	1
Under 37 CFR 1 16 and 1 17 Applicant claims small entity status.	139	130		'	Non-English specification	1
See 37 CFR 1.27	147	2,520	147	0.500	For filing a request for ex parte	7
2. Payment Enclosed:  Check Credit card Money Order Other	112	920*	112	020*	reexamination Requesting publication of SIR prior to Examiner action	1
Order Order	113	1,840*	113		Requesting publication of SIR after	1
FEE CALCULATION	-	,			· · · · · · · · · · · · · · · · · · ·	1
1. BASIC FILING FEE	115	110			Extension for reply within first month	$\dashv$
Large Small Entity	116	400			Extension for reply within second month	4
Fee Fee Fee Fee Description Code (\$) Code (\$) Fee Paid	117	920			Extension for reply within third month	4
101 740 201 370 Utility filing fee 370	118	1,440			Extension for reply within fourth month	4
106 330 206 165 Design filing fee	128	1,960			Extension for reply within fifth month	4
107 510 207 255 Plant filing fee	119	320			Notice of Appeal	4
108 740 208 370 Reissue filing fee	120	320			Filing a brief in support of an appeal	4
114 160 214 80 Provisional filing fee	121	280			Request for oral hearing	1
	138	1,510			Petition to institute a public use proceeding	4
SUBTOTAL (1) (\$)370.00	140	110	240		Petition to revive - unavoidable	╛
2. EXTRA CLAIM FEES	141	1,280	241	640	Petition to revive - unintentional	4
Fee from Extra Claims below Fee	142	1,280	242	640	) Utility issue fee (or reissue)	
Total Claims 7 -20**= 0 X =	143	460	243		Design issue fee	4
Independen 7 -3**= 4 X 42 = 168	144	620	0 244		) Plant issue fee	
Multiple Dependent	122	130	0 122	130	Petitions to the Commissioner	$\perp$
	123	50	0 123	50	O Processing fee under 37 CFR 1.17(q)	
Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (S) Code (\$)	126	180	0 126	180	Still	1
103 18 203 9 Claims in excess of 20	581	40	0 581	40	Recording each patent assignment per property (times number of properties)	
102 84 202 42 Independent claims in excess of 3	146	740	0 246	370	o Filing a submission after final rejection (37 CFR § 1.129(a))	]
104 280 204 140 Multiple dependent claim, if not paid	149	740	0 249	370	0 For each additional invention to be examined (37 CFR § 1 129(b))	
109 84 209 42 **Reissue independent claims over original patent	179	740	0 279	370	0 Request for Continued Examination (RCE)	4
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	169	900	0 169	900	O Request for expedited examination of a design application	4
SUBTOTAL (2) (\$) 168.00	l <b>i</b>	fee (spe				1
**or number previously paid, if greater, For Reissues, see above	suBTC	STAL (	Basic Fili	ling Fee I	Paid (\$)	

SUBMITTED BY 281-333-3413 41,866 Telephone Name (Print/Type) Lance K Ishimoto November 9, 2001 DAVIDW. HIBLER Signature Pancet Splinger by Davil W. There 1286.NO.41,071

Complete (if applicable

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization of PTO-2038.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231

## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Walke et al.

U.S. Ser. No.:

To Be Assigned

Attorney Docket No.: LEX-0268-USA

Filing Date:

November 9, 2001

For:

Novel Human Secreted Proteins and Polynucleotides Encoding the Same

## **VERIFIED STATEMENT**

Commission for Patents Washington, D.C. 20231

Sir:

- I, DRENDA D. THOMAS, do declare and state as follows:
- 1. I prepared a Sequence Listing in paper and computer readable form under 37 C.F.R. Sec. 1.821-1.825 in connection with the above-captioned patent application.
- 2. I hereby state that the contents of the paper and computer readable copies of the Sequence Listing are the same.

Signed,

November 9, 2001

Date

Drenda D. Thomas